primary sjögren's syndrome
Showing 1 - 25 of 31
Primary Sjögren's Syndrome Trial (Efgartigimod, Placebo)
Not yet recruiting
- Primary Sjögren's Syndrome
- Efgartigimod
- Placebo
- (no location specified)
Apr 5, 2023
Primary Sjögren's Syndrome Trial in Worldwide (S95011 concentrate for solution for infusion, Placebo concentrate for solution
Active, not recruiting
- Primary Sjögren's Syndrome
- S95011 concentrate for solution for infusion
- Placebo concentrate for solution for infusion
-
Beverly Hills, California
- +27 more
Jan 13, 2023
Primary Sjogren's Syndrome Trial in China (Telitacicept 80 mg, Telitacicept 160 mg, Placebo)
Not yet recruiting
- Primary Sjogren's Syndrome
- Telitacicept 80 mg
- +2 more
-
Bengbu, Anhui, China
- +67 more
Jan 5, 2023
Healthy Participants, Primary Sjögren's Syndrome Trial in Berlin (BMS-986325, Placebo for BMS-986325)
Recruiting
- Healthy Participants
- Primary Sjögren's Syndrome
- BMS-986325
- Placebo for BMS-986325
-
Berlin, GermanyLocal Institution - 0001
Jul 11, 2022
Primary Sjögren's Syndrome Trial in Hangzhou (Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets)
Recruiting
- Primary Sjögren's Syndrome
- Iguratimod Tablets
- Hydroxychloroquine Sulfate Tablets
-
Hangzhou, Zhejiang, ChinaSecond affiliated hospital of zhejiang university,school of medi
Mar 23, 2022
Primary Sjögren's Syndrome Trial in Beijing (Tofacitinib)
Recruiting
- Primary Sjögren's Syndrome
-
Beijing, Beijing, ChinaDepartment of Rheumatology and Immunology, Peking University Peo
Feb 28, 2022
Primary Sjogren's Syndrome Trial in Palo Alto (tibulizumab (LY3090106))
Withdrawn
- Primary Sjogren's Syndrome
- tibulizumab (LY3090106)
-
Palo Alto, CaliforniaStanford University
Jan 12, 2022
Primary Sjögren's Syndrome Trial in Yantai (Placebo, RC18 240 mg, RC18 160 mg)
Completed
- Primary Sjögren's Syndrome
- Placebo
- +2 more
-
Yantai, Shandong, ChinaRemegen,Ltd.
Jan 7, 2022
The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
Not yet recruiting
- Primary Sjögren's Syndrome
- Patients group
-
Çankaya, Ankara, TurkeyGazi University
Oct 5, 2021
Primary Sjögren's Syndrome Trial in Berlin (VAY736, Placebo)
Completed
- Primary Sjögren's Syndrome
- VAY736
- Placebo
-
Berlin, GermanyNovartis Investigative Site
Sep 30, 2021
Turkish Version of Primary Sjögren Syndrome Quality of Life
Recruiting
- Primary Sjögren's Syndrome
- Survey study
-
Ankara, TurkeyGazi University
Aug 31, 2021
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's
Recruiting
- Primary Sjögren's Syndrome
- Blood samples
-
Bourgoin-Jallieu, France
- +7 more
Jul 23, 2021
Primary Sjogren's Syndrome, Interstitial Lung Disease Trial in Shanghai (Jianfei Kangfu Cao, lung rehabilitation training)
Recruiting
- Primary Sjogren's Syndrome
- Interstitial Lung Disease
- Jianfei Kangfu Cao
- lung rehabilitation training
-
Shanghai, Shanghai, ChinaLonghua Hospital Affiliated to Shanghai University of Traditiona
Feb 24, 2021
Primary Sjögren's Syndrome Trial in Worldwide (CFZ533 active - Cohort 1, CFZ533 - Cohort 1, CFZ533 active - Cohort 2)
Completed
- Primary Sjögren's Syndrome
- CFZ533 active - Cohort 1
- +5 more
-
Boston, Massachusetts
- +8 more
Dec 9, 2020
Primary Sjögren's Syndrome Trial in Le Kremlin Bicêtre (No intervention)
Recruiting
- Primary Sjögren's Syndrome
- No intervention
-
Le Kremlin Bicêtre, Val De Marne, FranceHopital Bicêtre
Mar 12, 2020
Ultrasound Abnormalities of Salivary Glands in Primary Sjögren's
Unknown status
- Primary sjögren's Syndrome
-
Brest, France
- +2 more
Dec 26, 2019
Primary Sjögren's Syndrome Trial in Worldwide (AMG 557/MEDI5872, Placebo)
Completed
- Primary Sjögren's Syndrome
- AMG 557/MEDI5872
- Placebo
-
San Francisco, California
- +12 more
Feb 27, 2019
Primary Sjögren's Syndrome Trial in United States (Baminercept, Placebo)
Terminated
- Primary Sjögren's Syndrome
- Baminercept
- Placebo
-
Los Angeles, California
- +8 more
Dec 31, 2018
Primary Sjögren's Syndrome Trial in France (skin biopsy)
Completed
- Primary Sjögren's Syndrome
- skin biopsy
-
Albi, France
- +6 more
Jan 10, 2019
Primary Sjögren's Syndrome Trial in Beijing (hrIL-2 active, hrIL-2 )
Completed
- Primary Sjögren's Syndrome
- hrIL-2 active
- hrIL-2 placebo
-
Beijing, Beijing, ChinaDepartment of Rheumatology and Immunology, Peking University Peo
Mar 13, 2018